Clinical trials: Neoadjuvant Treatment
NSCLC (Non-small Cell Lung Cancer), EGFR
Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC
Exploring the efficacy and safety of firmonertinib combined with anlotinib and platinum-based doublet chemotherapy as neoadjuvant therapy in patients with EGFR-mutant resectable NSCLC
- Conditions
- NSCLC (Non-small Cell Lung Cancer), EGFR, Neoadjuvant Therapy
- Trial name
- NCT07807722
- Testing
- Firmonertinib combined anlotinib and chemotehrapy
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Hubei Cancer Hospital
Esophageal Squamous Cell Carcinoma
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
This is a prospective, multi-cohort, exploratory clinical study designed to evaluate the efficacy and safety of neoadjuvant adebrelimab combined with chemotherapy in patients with resectable locally advanced thoracic esophageal…
- Trial name
- NCT07452601
- Testing
- Adebrelimab plus nab-paclitaxel and cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tang-Du Hospital
Multiple Myeloma
Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD)
This is an italian multicenter study to determine whether maintenance treatment with Lenalidomide-based regimen significantly increases the rate of molecular remission in patients achieving at least a VGPR after therapy with new…
- Trial name
- MRD (NCT03433365)
- Testing
- MRD analysis
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Fondazione EMN Italy Onlus
Cutaneous Squamous Cell Carcinoma
Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery
To determine the histopathological response rate to neo-adjuvant nivolumab and nivolumab plus ipilimumab at time of standard of care(surgery ± radiotherapy).in patients with cutaneous squamous cell carcinoma.
- Trial name
- MATISSE (NCT04620200)
- Testing
- Nivolumab, Ipilimumab
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer, Prostate Adenocarcinoma
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy.
- Trial name
- NCT05726292
- Testing
- Relacorilant, Enzalutamide, Androgen Deprivation Therapy
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Chicago
Lung Cancer
Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
Lung cancer is a malignant tumor with the highest incidence and mortality rate of cancer patients worldwide. Traditional treatments for lung cancer include surgery, radiotherapy and chemotherapy, etc.
- Trial name
- NCT06216782
- Testing
- Non-intervention
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Papillomavirus Infections, Oropharyngeal Neoplasms
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
Background: Researchers have found a new way to treat cancer. The therapy used in this study is called E7 TCR T cell therapy. This therapy is a type of treatment in which a participant s T cells (a type of immune system white…
- Trial name
- NCT04044950
- Testing
- E7 TCR
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer
After a core biopsy of the tumor is obtained, patients with locally advanced breast cancer are randomized to receive 4 cycles of full dose doxorubicin (75 mg/m2 e3w) or docetaxel (100 mg/m2 e3w).
- Trial name
- NCT00123929
- Testing
- docetaxel, doxorubicin
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Hospital San Carlos, Madrid
Colon Cancer, Neoadjuvant Therapies
Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial
Most colorectal cancers belong to the microsatellite stable (MSS) or proficient mismatch repair (pMMR) subtypes, with limited response to PD-1 inhibitors.
- Conditions
- Colon Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiation Therapy
- Trial name
- MODIFI-L (NCT07279077)
- Testing
- Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Primary Breast Cancer
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
The primary objective of this trial is to compare the rate of pathologically complete remissions achieved using a preoperative dose-intensified 8 week therapy consisting of adriamycin and docetaxel with a preoperative sequential…
- Trial name
- NCT00793377
- Testing
- Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
- Where
- Germany
- Volunteers
- 913 people
- Sponsor
- GBG Forschungs GmbH
Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
Head and Neck Squamous Cell Carcinoma (HNSCC) is the most common malignant tumor of the head and neck, accounting for 90% of head and neck malignancies, and 16% to 40% of systemic malignancies.
- Trial name
- NCT04947241
- Testing
- PD-1 inhibitor+ Gemcitabine + Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Breast Cancer
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00072319
- Testing
- filgrastim, cyclophosphamide, epirubicin hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Colorectal Cancer
Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer
To explore the efficacy and safety of pembrolizumab in combination with bevacizumab and CapeOX neoadjuvant therapy for the treatment of RAS-mutated, BRAF wild-type, microsatellite-stabilized, locally advanced colorectal cancer.
- Trial name
- NCT06550453
- Testing
- Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- yangjianjun
Squamous Cell Carcinoma of the Head and Neck
Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.
A single-arm, single-center clinical trial evaluating efficacy (Phase #)
- Trial name
- NCT07550972
- Testing
- A single-arm, single-center clinical trial evaluating efficacy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Provincial People's Hospital
Stomach Neoplasms
Docetaxel in Locally Advanced Gastric Adenocarcinoma
Study objectives: To determine Ro resection rate of Docetaxel, cisplatin and fluorouracil combination for the treatment of neoadjuvant gastric carcinoma.
- Trial name
- NEOTAX (NCT00343239)
- Testing
- Docetaxel, Cisplatin, Fluorouracil
- Where
- Turkey (Türkiye)
- Volunteers
- 59 people
- Sponsor
- Sanofi
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
This phase II trial studies how well eltrombopag olamine works in improving the recovery of platelet counts in older patients with Acute Myeloid Leukemia (AML) undergoing induction (the first treatment given for a disease)…
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
- Trial name
- NCT02071901
- Testing
- eltrombopag olamine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Case Comprehensive Cancer Center
Locally Advanced Gastric Adenocarcinoma
Effect of High Protein ONS on Older Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy
This interventional prospective randomized controlled study was conducted to compare the effects of high-protein oral nutritional supplement (ONS) and medical nutritional therapy to medical nutrition therapy alone on nutritional…
- Trial name
- NCT06645912
- Testing
- oral nutritional supplement
- Where
- Turkey (Türkiye)
- Volunteers
- 46 people
- Sponsor
- Erzincan Binali Yildirim University Mengucek Gazi Training and Research Hospital
Gastric Cancer
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
Gastric cancer remains a significant global public health problem. Although in developed countries its incidence has dramatically decreased, on a worldwide scale it is still a leading cause of cancer-related deaths.
- Trial name
- TOPGEAR (NCT01924819)
- Testing
- Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel, Preoperative chemoradiotherapy, Gastric resection
- Where
- 59 sites in Australia, Belgium and 8 more
- Volunteers
- 574 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Breast Cancer Female
Axillary Sentinel or Targeted Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy in Node-positive Breast Cancer
This randomized phase II trial investigates the effectiveness of axillary sentinel or targeted lymph node biopsy alone after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial axillary metastasis.
- Trial name
- NCT05141630
- Testing
- sentinel lymph node biopsy or targeted axillary dissection alone
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Ultrasound
Sonazoid Contrast-enhanced Ultrasound in Assessing Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer Patients.
Sonazoid as a new generation of ultrasound contrast agent.This study based on the features of Sonazoid specific angiography and high mechanical index,the role of Sonazoid in assessing effectiveness of neoadjuvant chemotherapy in…
- Trial name
- NCT04657341
- Where
- China
- Volunteers
- 1,012 people
- Sponsor
- Chinese PLA General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.